Literature DB >> 14688411

Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.

Eric M Reiman1, Kewei Chen, Gene E Alexander, Richard J Caselli, Daniel Bandy, David Osborne, Ann M Saunders, John Hardy.   

Abstract

Fluorodeoxyglucose positron emission tomography (PET) studies have found that patients with Alzheimer's dementia (AD) have abnormally low rates of cerebral glucose metabolism in posterior cingulate, parietal, temporal, and prefrontal cortex. We previously found that cognitively normal, late-middle-aged carriers of the apolipoprotein E epsilon4 allele, a common susceptibility gene for late-onset Alzheimer's dementia, have abnormally low rates of glucose metabolism in the same brain regions as patients with probable AD. We now consider whether epsilon4 carriers have these regional brain abnormalities as relatively young adults. Apolipoprotein E genotypes were established in normal volunteers 20-39 years of age. Clinical ratings, neuropsychological tests, magnetic resonance imaging, and PET were performed in 12 epsilon4 heterozygotes, all with the epsilon3/epsilon4 genotype, and 15 noncarriers of the epsilon4 allele, 12 of whom were individually matched for sex, age, and educational level. An automated algorithm was used to generate an aggregate surface-projection map that compared regional PET measurements in the two groups. The young adult epsilon4 carriers and noncarriers did not differ significantly in their sex, age, educational level, clinical ratings, or neuropsychological test scores. Like previously studied patients with probable AD and late-middle-aged epsilon4 carriers, the young epsilon4 carriers had abnormally low rates of glucose metabolism bilaterally in the posterior cingulate, parietal, temporal, and prefrontal cortex. Carriers of a common Alzheimer's susceptibility gene have functional brain abnormalities in young adulthood, several decades before the possible onset of dementia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688411      PMCID: PMC314177          DOI: 10.1073/pnas.2635903100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  59 in total

1.  Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease.

Authors:  K Meguro; X Blaizot; Y Kondoh; C Le Mestric; J C Baron; C Chavoix
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

2.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.

Authors:  Gene E Alexander; Kewei Chen; Pietro Pietrini; Stanley I Rapoport; Eric M Reiman
Journal:  Am J Psychiatry       Date:  2002-05       Impact factor: 18.112

3.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

4.  Childhood mental ability and dementia.

Authors:  L J Whalley; J M Starr; R Athawes; D Hunter; A Pattie; I J Deary
Journal:  Neurology       Date:  2000-11-28       Impact factor: 9.910

5.  Educational attainment and socioeconomic status of patients with autopsy-confirmed Alzheimer disease.

Authors:  D G Munoz; G R Ganapathy; M Eliasziw; V Hachinski
Journal:  Arch Neurol       Date:  2000-01

6.  Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.

Authors:  E M Reiman; R J Caselli; K Chen; G E Alexander; D Bandy; J Frost
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

7.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.

Authors:  D H Silverman; G W Small; C Y Chang; C S Lu; M A Kung De Aburto; W Chen; J Czernin; S I Rapoport; P Pietrini; G E Alexander; M B Schapiro; W J Jagust; J M Hoffman; K A Welsh-Bohmer; A Alavi; C M Clark; E Salmon; M J de Leon; R Mielke; J L Cummings; A P Kowell; S S Gambhir; C K Hoh; M E Phelps
Journal:  JAMA       Date:  2001-11-07       Impact factor: 56.272

8.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.

Authors:  Kooresh Shoghi-Jadid; Gary W Small; Eric D Agdeppa; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Stephen Read; Nagichettiar Satyamurthy; Andrej Petric; Sung-Cheng Huang; Jorge R Barrio
Journal:  Am J Geriatr Psychiatry       Date:  2002 Jan-Feb       Impact factor: 4.105

9.  A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain.

Authors:  Chester A Mathis; Brian J Bacskai; Stephen T Kajdasz; Megan E McLellan; Matthew P Frosch; Bradley T Hyman; Daniel P Holt; Yanming Wang; Guo-Feng Huang; Manik L Debnath; William E Klunk
Journal:  Bioorg Med Chem Lett       Date:  2002-02-11       Impact factor: 2.823

10.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.

Authors:  G W Small; L M Ercoli; D H Silverman; S C Huang; S Komo; S Y Bookheimer; H Lavretsky; K Miller; P Siddarth; N L Rasgon; J C Mazziotta; S Saxena; H M Wu; M S Mega; J L Cummings; A M Saunders; M A Pericak-Vance; A D Roses; J R Barrio; M E Phelps
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

View more
  412 in total

1.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.

Authors:  William J Jagust; Dan Bandy; Kewei Chen; Norman L Foster; Susan M Landau; Chester A Mathis; Julie C Price; Eric M Reiman; Daniel Skovronsky; Robert A Koeppe
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

2.  The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects.

Authors:  Mert R Sabuncu; Randy L Buckner; Jordan W Smoller; Phil Hyoun Lee; Bruce Fischl; Reisa A Sperling
Journal:  Cereb Cortex       Date:  2011-12-13       Impact factor: 5.357

Review 3.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

4.  Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence.

Authors:  Jia Yao; Ryan T Hamilton; Enrique Cadenas; Roberta Diaz Brinton
Journal:  Biochim Biophys Acta       Date:  2010-06-09

5.  Association between mitochondrial DNA variations and Alzheimer's disease in the ADNI cohort.

Authors:  Anita Lakatos; Olga Derbeneva; Danny Younes; David Keator; Trygve Bakken; Maria Lvova; Marty Brandon; Guia Guffanti; Dora Reglodi; Andrew Saykin; Michael Weiner; Fabio Macciardi; Nicholas Schork; Douglas C Wallace; Steven G Potkin
Journal:  Neurobiol Aging       Date:  2010-06-11       Impact factor: 4.673

Review 6.  Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease.

Authors:  Kassandra Kisler; Amy R Nelson; Axel Montagne; Berislav V Zlokovic
Journal:  Nat Rev Neurosci       Date:  2017-05-18       Impact factor: 34.870

Review 7.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 8.  Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: a systematic review.

Authors:  Konstantinos Ioannis Avgerinos; Grigorios Kalaitzidis; Antonia Malli; Dimitrios Kalaitzoglou; Pavlos Gr Myserlis; Vasileios-Arsenios Lioutas
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

Review 9.  Microglia and macrophage metabolism in CNS injury and disease: The role of immunometabolism in neurodegeneration and neurotrauma.

Authors:  Nicholas A Devanney; Andrew N Stewart; John C Gensel
Journal:  Exp Neurol       Date:  2020-04-11       Impact factor: 5.330

Review 10.  Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.

Authors:  Alexander Drzezga; Daniele Altomare; Cristina Festari; Javier Arbizu; Stefania Orini; Karl Herholz; Peter Nestor; Federica Agosta; Femke Bouwman; Flavio Nobili; Zuzana Walker; Giovanni Battista Frisoni; Marina Boccardi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.